The Quiet Revolution in NIH's FY26 Reset: How Direct-to-Phase II STTR Awards Rewire the University Spinout Economy — and What Tech Transfer Offices Need to Do Before September 8

The most consequential change in the National Institutes of Health's FY26 SBIR and STTR reset is also the one that has received the least industry attention. When NIH reposted the omnibus solicitations on June 1 with a uniform September 8 first-deadline, it quietly extended Direct-to-Phase II eligibility — a pathway that lets qualified applicants skip the Phase I feasibility stage and apply directly for a roughly two-year, roughly $2 million Phase II award — to the STTR program for the first time in the program's history. The headline matters to a relatively narrow but strategically important slice of the small-business research ecosystem: university-affiliated small businesses whose science depends on a formal academic partnership and whose feasibility evidence sits inside the university's existing research record rather than in a separate company-funded Phase I project.

For tech transfer offices, faculty founders, university research administrators, and small-business CEOs who emerged from academic labs, the Direct-to-Phase II STTR launch is the most significant structural shift in the federal university-spinout funding pipeline in a decade. The September 8 first-deadline gives prepared teams a runway of less than three months to assemble feasibility documentation, structure subaward terms, finalize IP licensing positions, and submit a competitive application against a brand-new study section dynamic. The teams that move now will own the first Direct-to-Phase II STTR cohort. The teams that wait for the official guide notice to make the playbook concrete will be writing the application under deadline pressure in a policy environment that has materially shifted under them.

This is a deep read of what the new pathway actually changes, what the structural requirements look like in practice for university-affiliated small businesses, and what the institutional preparation looks like at universities whose tech transfer offices have not yet seen a Direct-to-Phase II STTR application come across the desk.

What Direct-to-Phase II Is — and Why STTR Eligibility Is New

NIH's Direct-to-Phase II SBIR pathway has existed since 2014. The mechanism lets a small business that can document Phase I-equivalent feasibility — typically peer-reviewed publications, prior non-NIH funded research, or other independent evidence that the technology works at the proof-of-concept level — apply directly for a Phase II award without first competing for a separate Phase I grant. The compression effect on the funding timeline is meaningful. A traditional SBIR pathway runs roughly six months for Phase I application and review, six months of Phase I performance, six months for Phase II application and review, and then Phase II performance. Direct-to-Phase II collapses the first eighteen months of that sequence into a single application cycle. For a small business that already has the feasibility evidence in hand, Direct-to-Phase II shifts the funding clock from roughly three years to roughly fifteen months.

What Direct-to-Phase II has not previously included is the STTR program. STTR is structurally distinct from SBIR in one critical way: it requires a formal collaboration with a nonprofit research institution — typically a university — and it requires that the research institution receive no less than 30 percent of the total award dollars as a subaward. The structure is designed to fund small businesses whose science is inseparable from an academic partnership, and the unit of analysis is the small business plus the research institution working together under a formal cooperative research agreement.

The 2025 reauthorization of the SBIR and STTR programs created the statutory basis for adding Direct-to-Phase II eligibility to STTR. NIH's FY26 omnibus reposting on June 1 was the program's first opportunity to operationalize that authority, and the agency took it. For the first time, university-affiliated small businesses whose feasibility evidence rests inside a university research record can apply directly for a Phase II STTR award without first running a separate Phase I cycle.

That change matters because the population of small businesses for whom STTR is the right pathway has historically been the population of university spinouts. The faculty founder who is also the small business CEO; the postdoctoral researcher who has formed a company to advance research that began in an academic lab; the small business that has licensed a technology from a university and continues to depend on the originating laboratory for ongoing scientific collaboration — these are the canonical STTR applicants, and the Phase I requirement has historically forced these teams through a year-plus of separate Phase I performance before they could access the larger Phase II award that their science was structurally ready for. Direct-to-Phase II STTR is the structural fix for that timeline mismatch.

The Feasibility Evidence Question: What Counts and What Doesn't

The single most important technical question for a Direct-to-Phase II STTR applicant is what evidence the team can put in the application to demonstrate Phase I-equivalent feasibility. NIH's guidance on Direct-to-Phase II SBIR has historically been demanding on this point, and there is no reason to expect the STTR equivalent to be less so.

The strongest evidence is a peer-reviewed publication in a credible journal that demonstrates the specific technical milestones a Phase I award would have funded. The publication does not need to be authored by the small business; in the STTR context, it often will not be, because the underlying science typically sits inside the university's research record under the lead faculty member's name. What matters is that the publication can be cited as evidence that the key technical milestones — typically in vivo proof of concept, key efficacy or feasibility demonstrations in the relevant model system, or the equivalent in non-biological domains — have been achieved and independently reviewed.

The next-strongest evidence is non-NIH-funded research that has been completed by the team and documented in a way that allows reviewers to assess its rigor. Foundation-funded research, NSF-funded research, internal company research that has been independently reviewed, and research conducted under industry partnerships can all serve as feasibility evidence if the documentation supports the rigor argument. The trap is research that exists in lab notebooks but has never been written up or independently reviewed; that evidence is generally not strong enough to support a Direct-to-Phase II application, regardless of how compelling the data may appear to the team that produced it.

The weakest evidence — and the most common source of unsuccessful Direct-to-Phase II applications — is preliminary data that the team itself believes is conclusive but that has not been subjected to independent peer review. NIH study sections take the feasibility threshold seriously, and applications that rest on team-internal data without external validation tend to perform poorly. The institutional advice that any tech transfer office should be giving its faculty founders this month is to inventory the publications and externally validated research that bear on the specific technical milestones the proposed Phase II would advance, and to assess honestly whether the evidence base supports a Direct-to-Phase II application or whether the team is better positioned to apply for Phase I.

The honest assessment is consequential. A Direct-to-Phase II application that does not clear the feasibility threshold is not redirected to the Phase I pool; it is reviewed against the Phase II quality bar, and it loses. Teams that misjudge the feasibility threshold are not just unsuccessful in the Direct-to-Phase II application; they are out of the September 8 cycle entirely.

The 30 Percent Subaward Structure: Where University Spinouts Get Tangled

The STTR program's requirement that the research institution receive at least 30 percent of the total award dollars as a subaward is a structural feature that interacts with the Direct-to-Phase II pathway in ways that most university-affiliated small businesses have not yet thought through.

The 30 percent floor applies to the total award value, not to any single year. A two-year Phase II STTR award of roughly $2 million implies a research-institution subaward of roughly $600,000 over the two-year period. The work to be performed under that subaward has to be substantive, scientifically necessary, and independently justified in the application narrative. NIH study sections do not respond well to subaward structures that look like budget filler designed to satisfy the 30 percent floor without a credible scientific role for the research institution.

For university spinouts in particular, the subaward structure typically reflects the ongoing scientific partnership between the small business and the laboratory of the founding faculty member. The faculty member is often the PI or co-PI on the STTR application, the laboratory continues to perform a defined slice of the Phase II research, and the subaward funds that work. The mechanics of the arrangement — how the faculty member's time is allocated between the small business and the university, how the laboratory's personnel and resources are deployed against the Phase II research, how the small business and the laboratory coordinate on intellectual property generated under the award — are all questions that have to be sorted out before the application is submitted, and they are questions that benefit from a tech transfer office that has done this kind of structuring before.

The Direct-to-Phase II pathway accelerates this entire arrangement. In a traditional STTR Phase I cycle, the small business and the university have six months of Phase I performance to work out the operational details of the partnership before moving into the larger Phase II. Direct-to-Phase II compresses that work into the pre-submission preparation period. Tech transfer offices that have a standardized STTR subaward template, a clear policy on faculty member time allocation, and a worked-out approach to IP generated under federally funded research are ready to support a Direct-to-Phase II application on the September 8 timeline. Tech transfer offices that have to draft these arrangements from a blank page for each new application are facing a tight runway.

The IP Licensing Question: License-Back, Background IP, and the Federal Funding Overlay

Direct-to-Phase II STTR applications raise IP licensing questions that the structure of the program does not fully resolve at the application stage but that nonetheless need to be sorted before the team can credibly represent the commercialization pathway to reviewers.

The first question is the underlying technology license. Most university spinout small businesses have licensed a foundational technology from the university through the tech transfer office under a license agreement that predates the STTR application. That license agreement governs the small business's right to commercialize the underlying technology, and it is the legal predicate for everything the small business does downstream. NIH does not require the license agreement to be submitted with the STTR application, but reviewers expect to see in the commercialization plan a clear articulation of the IP position that the small business holds and the basis for that position.

The second question is the IP that will be generated under the Phase II award. Federal funding triggers Bayh-Dole obligations and march-in rights that interact with the existing license arrangement in ways that vary by institution. Universities typically have standard policies for handling subject inventions made under federally funded subawards, but the policies are not uniform across institutions, and small businesses whose Phase II IP will be jointly generated by the small business and the university laboratory should expect to negotiate specific terms for handling new inventions before the application is submitted.

The third question is license-back arrangements for university researchers who continue to work on the technology under the STTR subaward. Tech transfer offices often retain license-back rights for academic research that uses the licensed technology, and the boundaries between commercialization-directed research and continued academic research can become operationally complex when the same technology is being advanced under both arrangements simultaneously. The institutional clarity on those boundaries — what counts as Phase II work funded by the federal subaward, what counts as continuing academic research under the original license-back, and how the small business and the laboratory coordinate to avoid working at cross-purposes — is something that needs to be in place before the Phase II award begins, and ideally before the application is submitted.

The institutional pattern that this implies is one in which the tech transfer office is a central participant in the Direct-to-Phase II STTR application process, not a downstream administrator who signs off on the subaward after the science has been worked out. For universities whose tech transfer offices have historically been peripheral to STTR application strategy, the Direct-to-Phase II launch is a forcing function to elevate the office's involvement.

What Tech Transfer Offices Should Do This Month

For university tech transfer offices that anticipate Direct-to-Phase II STTR applications from faculty-founded small businesses in the September 8 cycle, several institutional preparations are worth completing this month rather than during the application drafting period.

The first is to identify the faculty founders and university-affiliated small businesses in the institution's portfolio whose feasibility evidence base is plausibly Phase I-equivalent. Most universities have a list of active license agreements with spinout companies, and the subset of those companies that are advancing technologies in the NIH-relevant biomedical and biotechnology space is the natural population to engage. A short outreach campaign — a one-page summary of the Direct-to-Phase II STTR pathway, an offer to discuss feasibility evidence and subaward structuring, and a clear timeline for institutional support through the September 8 cycle — is a high-leverage use of tech transfer office time.

The second is to update the standardized STTR subaward template to reflect the Direct-to-Phase II structure. The traditional STTR subaward template was designed around Phase I performance and a separate Phase II application; the Direct-to-Phase II structure compresses the timeline and changes the operational details. Tech transfer offices that have not yet drafted a Direct-to-Phase II STTR subaward template will be doing the drafting in the application window.

The third is to coordinate with the university's sponsored research office on the institutional review and signoff process. Direct-to-Phase II STTR applications require institutional certifications that the university is willing and able to perform the subaward work, that the IP position is consistent with university policy, and that the conflict-of-interest disclosures for faculty members who are also small business officers have been reviewed and managed. The institutional sign-off process is often the rate-limiting step in the application timeline, and tech transfer offices that have not pre-coordinated with sponsored research will find the institutional sign-off arriving close to the submission deadline.

The fourth is to engage faculty founders on the personal allocation question. Faculty members who are also small business CEOs or chief scientific officers have ongoing university responsibilities that interact with the STTR PI role in specific ways. NIH STTR rules require the PI to be primarily employed by either the small business or the research institution, and the implications for faculty effort allocation, university effort certification, and small business employment terms vary by university policy. The clarity on which entity the faculty member is primarily employed by — and the related effort allocation — needs to be in place at the time of application, and changes to the arrangement after award are often constrained by both NIH policy and university policy.

The Competitive Landscape: Why September 8 Is Different

The September 8 cycle is the first cycle of the FY26 reset, and it is the cycle in which the new Direct-to-Phase II STTR pathway will receive its first applications. The study section dynamics for the cycle will be different from those that any prior STTR cycle has seen, in ways that matter for application strategy.

The study sections will be reviewing Direct-to-Phase II STTR applications for the first time. The reviewers will be calibrating their expectations against a population of applications that has not yet existed, and the early-cycle calibration tends to favor applications that present feasibility evidence and Phase II project design in a way that closely mirrors the framework reviewers are familiar with from the SBIR Direct-to-Phase II context. Applications that look like they are inviting reviewers into an unfamiliar paradigm tend to perform less well than applications that fit the existing reviewer framework while taking advantage of the new STTR-specific structural features.

The applicant pool will be unusually heavy with strategically prepared teams. University-affiliated small businesses that have been waiting for STTR Direct-to-Phase II eligibility — and a number of them have been waiting for several years, since the policy conversation started — will be in the September 8 pool. The competitive intensity will be correspondingly higher than a typical STTR cycle.

The success rate for the first Direct-to-Phase II STTR cycle is, by definition, unknown. The Direct-to-Phase II SBIR pathway has historically had a lower success rate than the conventional Phase I-to-Phase II sequence, in part because the feasibility threshold is high and in part because the application is reviewed against the Phase II quality bar from the start. There is no reason to expect Direct-to-Phase II STTR to have a higher success rate than Direct-to-Phase II SBIR, and there are some reasons — the structural novelty, the first-cycle calibration dynamics, the institutional complexity of the subaward arrangements — to expect the success rate to be lower in the first cycle than it will be in subsequent cycles as the program settles.

The implication for application strategy is that teams should treat the September 8 cycle as a serious competition that requires the institutional preparation to support a Phase II-quality application, not as a faster lane to Phase II funding that bypasses some of the work of the traditional pathway. Teams that approach Direct-to-Phase II STTR as a shortcut will be the teams whose applications underperform. Teams that approach it as the structurally appropriate pathway for university-affiliated small businesses whose feasibility evidence is already in place will be the teams whose applications win.

Cross-Reference and Next Steps

For broader context on the NIH SBIR/STTR FY26 omnibus reset and the September 8 first-deadline, see the prior coverage of the NIH SBIR/STTR hiatus and reset. For applicants who are deciding between Phase I and Direct-to-Phase II strategies, the SBIR Phase I vs Phase II requirements and strategy guide covers the structural distinctions that bear on the choice. For first-time SBIR/STTR applicants from the university spinout space, the SBIR/STTR Grants for Startups first application guide walks through the foundational application mechanics that Direct-to-Phase II applicants still need to clear, regardless of which pathway they choose.

The Direct-to-Phase II STTR launch is the kind of policy change that quietly rewires an ecosystem. The university tech transfer offices, faculty founders, and small business CEOs who recognize what has shifted under them and move with appropriate urgency will be the ones whose institutional positioning improves in the FY26 cycle and the cycles that follow. The September 8 first-deadline is the moment in which the new structure goes live. For teams whose feasibility evidence is already in the published record, whose subaward arrangements are workable, and whose IP licensing position is clean, the moment is now.